Table 1.
Baseline characteristics of HIV-HBV co-infected participants. Unless otherwise stated in the characteristics description, numbers represent median (IQR) for continuous variables and n (percent) for categorical variables
| Characteristics | All participants (N = 139a) |
Participants with liver biopsy (N = 114a) |
|---|---|---|
| Age (years, mean (SD)) | N = 13,948.7(8.8) | N = 11,449.3 (9.0) |
| Gender | N = 139 | N = 114 |
| Male | 128 (92.1%) | 106 (93.0%) |
| Race/Ethnicity | N = 138 | N = 113 |
| Non-Hispanic White | 44 (31.8%) | 37 (32.7%) |
| Non-Hispanic Black | 70 (50.7%) | 58 (51.3%) |
| Non-Hispanic Asian | 5 (3.6%) | 5 (4.4%) |
| Other | 19 (13. 8%) | 13 (11.5%) |
| Weight (kg), male | N = 11,079.4 (67.3: 93.6) |
N = 9179.2 (66.2: 93.6) |
| Weight (kg), female |
N = 1094.0 (75.3: 112.5) |
N = 798.2 (82.5: 112.6) |
| Body mass index (kg/m2) | N = 11,825.8 (22.0: 31.2) | N = 9726.3 (22.0: 30.8) |
| Tobacco use | N = 139 | N = 114 |
| Never use a tobacco product | 32 (23.0%) | 26 (22.8%) |
| Formerly used a tobacco product | 42 (30.2%) | 36 (31.6%) |
| Currently used a tobacco product | 65 (46.8%) | 52 (45.6%) |
| Alcohol consumption | N = 138 | N = 114 |
| Low risk | 128 (92.8%) | 106 (93.8%) |
| Increasing risk | 9 (6.5%) | 7 (6.2%) |
| High risk | 1 (0.7%) | 0 (0.0%) |
| Tea cups per day | N = 138 | N = 114 |
| None | 51 (37.0%) | 39 (34.2%) |
| Occasionally, <1 per day | 62 (44.9%) | 54 (47.4%) |
| 1 per day | 12 (8.7%) | 10 (8.8%) |
| 2 per day | 9 (6.5%) | 7 (6.1%) |
| 3 or 4 per day | 2 (1.4%) | 2 (1.8%) |
| More than 4 per day | 2 (1.4%) | 2 (1.8%) |
| History of diabetes | 12 (8.6) | 10(8.8) |
| History of sexually transmitted diseases |
N = 12,681 (64.3%) | N = 10,870 (64.8%) |
| Estimated duration of HIV infection, years |
N = 12,019.5 (10.5: 25.0) | N = 10,220.0 (10.0: 25.0) |
| Estimated duration of HBV infection, years |
N = 10,314.0 (8.0: 20.0) |
N = 8714.0 (8.0: 22.0) |
| Presumed source of HIV | N = 124 | N = 105 |
| Sexually transmitted | 118 (95.2%) | 99 (94.3%) |
| Transfusion | 1 (0.8%) | 1 (1.0%) |
| Injection drug use | 3 (2.4%) | 3 (2.9%) |
| Other | 2 (1.6%) | 2 (1.9%) |
| Presumed source of Hepatitis B | N = 116 | N = 99 |
| Vertical transmission | 1 (0.9%) | 1 (1.0%) |
| Sexually transmitted | 107 (92.2%) | 87 (90.9%) |
| Transfusion | 3 (2.6%) | 3 (3.0%) |
| Injection drug use | 3 (2.6%) | 3 (3.0%) |
| Other | 2(1.7%) | 2 (2.0%) |
| History of cART use | N = 139 | N = 114 |
| Anti-HBV use | 138 (99.3%) | 114 (100.0%) |
| Tenofovir: alone | 13 (9.6%) | 12 (10.7%) |
| Tenofovir: alone or in combination | 103 (75.7%) | 87 (77.7%) |
| Emtricitabine: alone or in combination | 93 (68.4%) | 77 (68.8%) |
| Lamivudine: alone or in combination | 21 (15.4%) | 18 (16.1%) |
| Entecavir | 18 (13.2) | 16 (14.3%) |
| Tenofovir + emtricitabine | 90 (66.2) | 75 (67.0%) |
| Tenofovir + lamivudine | 9 (6.6) | 8 (7.1%) |
| Tenofovir + entecavir | 5 (3.7) | 5 (4.5%) |
| Lipodystrophy/lipoatrophy gradeb | N = 123 | N = 102 |
| 0 | 103 (83.7%) | 88 (86.3%) |
| 1 | 13 (10.6%) | 9 (8.8%) |
| 2 | 6 (4.9%) | 4 (3.9%) |
| 3 | 1 (0.8%) | 1 (1.0%) |
| HIV stagec | N = 107 | N = 86 |
| 1 | 73 (68.2%) | 63 (73.3%) |
| 2 | 17 (15.9%) | 11 (12.8%) |
| 3 | 8 (7.5%) | 5 (5.8%) |
| 4 | 9 (8.4%) | 7 (8.1%) |